A 12-Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Dose Range Finding Study to Evaluate the Efficacy of Oglemilast in the Treatment of Stable Mild to Moderate Persistent Asthma.

Trial Profile

A 12-Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Dose Range Finding Study to Evaluate the Efficacy of Oglemilast in the Treatment of Stable Mild to Moderate Persistent Asthma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs Oglemilast (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 25 Sep 2009 Planned end date changed from Sep 2009 to Jan 2010 as reported by ClinicalTrials.gov.
    • 10 Mar 2009 Planned number of patients changed from 230 to 282 based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top